Predictors of Bloodstream Infection in Patients Presenting With Cardiovascular Implantable Electronic Device Pocket Infection

Zereilda Esquer Garrigos,1,2 Merit P. George,1 Sarwat Khalil,1 Prakhar Vijayvargiya,1 Omar M. Abu Saleh,1 Paul A. Friedman,2 James M. Steckelberg,1 Daniel C. DeSimone,1 Walter R. Wilson,1,2 Larry M. Baddour,1,2 and M. Rizwan Sohail1,2

1Division of Infectious Diseases and 2Department of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester Minnesota

Background. Generator pocket infection is the most frequent presentation of cardiovascular implantable electronic device (CIED) infection. We aim to identify predictors of underlying bloodstream infection (BSI) in patients presenting with CIED pocket infection.

Methods. We retrospectively reviewed all adults with CIED pocket infection cared for at our institution from January 2005 through January 2016. The CIED pocket infection cases were then subclassified as with or without associated BSI. Variables with P values <.05 at univariate analysis were included in a multivariable model to identify independent predictors of underlying BSI.

Results. We screened 429 cases of CIED infection, and 95 met the inclusion criteria. Of these, 68 cases (71.6%) were categorized as non-BSI and 27 (28.4%) as BSI. There were no statistically significant differences in patient comorbid conditions or device characteristics between the 2 groups. In multivariable analysis, the presence of systemic inflammatory response syndrome criteria (tachycardia, tachypnea, fever or hypothermia, and leukocytosis or leukopenia) and hypotension were independent predictors of underlying BSI in patients presenting with CIED pocket infection. Overall, patients in the non-BSI group who did not receive pre-extraction antibiotics had a higher frequency of positive intraoperative pocket/device cultures than those with pre-extraction antibiotic exposure (79.4% vs 58.6%; P = .06).

Conclusions. Patients with CIED pocket infection who meet systemic inflammatory response syndrome criteria and/or are hypotensive at admission are more likely to have underlying BSI and should be started on empiric antibiotics after blood cultures are obtained. If these features are absent, it may be reasonable to withhold empiric antibiotics to optimize yield of pocket/device cultures during extraction.

Key words: bloodstream infection; cardiovascular implantable electronic device infections; generator-pocket infection; predictors; treatment.
clinical parameters: temperature $\geq 38.3^\circ C$ or $\leq 36^\circ C$, pulse rate $> 90$/min, respirations $> 20$/min, and WBC count $> 12000/\mu L$ or $< 4000/\mu L$. Hypotension was defined as systolic blood pressure $< 90$ mm Hg or a $\geq 40$ mm Hg from baseline.

Significant microbial growth from operative cultures was defined as isolation of $\geq 20$ colony-forming units from 10 mL of sonicate fluid, colony growth reported in $\geq 2$ quadrants of the culture plate from a single specimen, or microbial growth of the same organism reported from $\geq 2$ operative samples [8]. Device removal and associated complications were documented. The study was approved by the Mayo Clinic Institutional Review Board.

**Statistical Analysis**

We used $\chi^2$ tests for categorical variables and Wilcoxon rank sum tests to associate continuous variables with 2-level categorical data. We assessed the predictors of BSI using univariate and multivariable logistic regression models. Odds ratios, 95% confidence intervals, and likelihood ratio $P$ values were reported for the logistic models. Statistical tests were 2 sided, with differences considered statistically significant at $P < .05$. Analyses were performed using JMP 13.0 software (SAS Institute).

**RESULTS**

**Demographic, Clinical, and Device Data**

Overall, 429 cases of CIED infection were seen during the study period (Figure 1). Among those, 248 of 429 (57.8%) had inflammatory changes at the pocket site, and 95 of them met study criteria. The excluded cases are outlined in Figure 1. Of these 95 study subjects, 68 (71.6%) were classified as non-BSI and 27 (28.4%) as BSI. Demographic data and underlying comorbid conditions for both groups are summarized with statistical analysis in Table 1. There was no significant difference in the median age at presentation for the non-BSI and BSI groups. There was no difference in the prevalence of medical comorbid conditions or device characteristics between groups.

**Symptoms Reported at Initial Evaluation**

Concomitant lead or generator erosion was reported in 25 of 68 patients (36.7%) in the non-BSI group and 3 of 27 (11.1%) in the BSI group ($P = .01$). In the BSI group, pocket infection was complicated with CIED valvular endocarditis in 2 of 27 cases (both due to *Staphylococcus aureus*) and with CIED lead endocarditis in 5 of 27 (1 due to *S. aureus*, 2 due to *Enterococcus faecalis*, and 2 due to CoNS). There were 2 cases of CIED lead and tricuspid valve endocarditis related to *S. aureus*. A majority of patients in the non-BSI group reported symptoms at the pocket site $>14$ days in duration (60.2% vs 33.3%; $P = .02$). General malaise was reported more frequently in the BSI (92.8%) than in the non-BSI (2.9%) cohort ($P < .001$).

**Vital Signs at Initial Evaluation**

Patients with pocket infection and BSI had a higher median maximum temperature than the non-BSI group (38.1°C
Bloodstream Infection in CIED Pocket Infections

**Table 1.** Demographic, Clinical, and Device Characteristics of 95 Patients With CIED Pocket Infection

| Variable                          | Non-BSI Group (n = 68) | BSI Group (n = 27) | P Value |
|----------------------------------|------------------------|--------------------|---------|
| Demographics                     |                        |                    |         |
| Age, median (IQR), y             | 67 (53–81)             | 69 (58.8–77.7)     | .77     |
| Male sex                         | 48 (70.5)              | 18 (66.6)          | .71     |
| Comorbid conditions              |                        |                    |         |
| Type 2 diabetes mellitus         | 15 (22.0)              | 4 (14.8)           | .89     |
| Chronic kidney disease           | 13 (19.1)              | 4 (14.8)           | .62     |
| Chronic heart failure            | 40 (58.8)              | 20 (74)            | .16     |
| COPD                             | 7 (10.2)               | 2 (7.1)            | .66     |
| Immunosuppression                | 5 (7.3)                | 2 (7.4)            | .99     |
| Prosthetic valve                 | 11 (16.4)              | 7 (25.9)           | .27     |
| Previous CIED infection          | 4 (5.8)                | 3 (11.1)           | .38     |
| Device                           |                        |                    |         |
| Initial placement                | 18 (26.4)              | 9 (33.3)           | .50     |
| Device revision                  | 48 (70.5)              | 18 (66.6)          | .71     |
| ICD                              | 27 (39.7)              | 12 (44.4)          | .89     |
| Permanent pacemaker              | 26 (38.2)              | 9 (33.3)           |         |
| CRT                              | 15 (22)                | 6 (22.2)           |         |
| Time from implantation/revision  | 140 (35–623)           | 106.5 (22.2–756.7) | .35     |

**Laboratory Data at Initial Presentation**

The BSI group had a higher median WBC count at admission than the non-BSI group (12.4 × 10^9/L [IQR, 8.7–16.1 × 10^9/L] vs 7.2 × 10^9/L [5.6–9.1 × 10^9/L], respectively; P < .001), with leukocytosis or leukopenia present in 59.2% vs 2.9%, respectively (P < .001). The BSI cohort also had higher median serum creatinine (1.1 [IQR, 0.9–1.65] vs 1 [0.8–1.3] mg/dL; P = .04) and aspartate aminotransferase (29 U/L [25–47] vs 22 [20–27] U/L; P = .02) values. There were no statistically significant differences in platelet count, blood lactate level, erythrocyte sedimentation rate, or C-reactive protein level.

**Predictors of BSI**

We performed univariate and multivariable analysis of clinical predictors associated with BSI in patients presenting with CIED pocket infection. In the univariate analysis (Table 2), patients with BSI were more likely to meet SIRS criteria, have hypotension, and have ≥2 abnormal laboratory values (C-reactive protein, erythrocyte sedimentation rate, aspartate aminotransferase, and blood urea nitrogen). Symptom duration >14 days before presentation was correlated with a lower risk of BSI. Given the small sample size, only variables from the univariate analysis with P values <.05 were included in multivariable analysis.
analysis (Table 3). Independent variables associated with BSI in multivariable analysis included the presence of SIRS criteria and hypotension.

Antimicrobial Management and Operative Culture Yield
Management, operative culture yield and outcomes in all 95 patients with CIED pocket infection are summarized in Table 4. At admission, providers elected to withhold antimicrobials until device removal in slightly more than half of patients in the non-BSI group (57.3%) and in 1 of 25 in the BSI group. In this particular patient, no SIRS criteria were recorded at admission or laboratory abnormalities at presentation. Antibiotic therapy was started in this patient once blood culture results returned positive.

The median time off antibiotic therapy until device removal in the non-BSI group was 2 (IQR, 1–7) days. None of the patients in the non-BSI group showed clinical progression or deterioration while off antibiotic therapy. The device was removed in all patients in the non-BSI group and 25 of 27 (92.5%) in the BSI group. Of the 2 patients whose device was retained, 1 died of infection complications before the scheduled procedure and the other declined surgical intervention and was kept on life-long antibiotic suppression. Both received antimicrobials at the time of initial presentation.

Of the patients undergoing device removal, complications were reported in 1 patient in the non-BSI group, who had superior vena cava rupture, and in 1 in the BSI group, who experienced cardiac arrhythmia and subsequently died. However, none of the patients in whom antibiotic therapy was initially withheld had infection-related complications. No infection relapse or recurrence, after reimplantation of a new device, was reported in patients in whom initial antibiotic therapy was withheld until extraction of the infected device.

### Table 2. Clinical Presentation in 95 Patients With CIED Pocket Infection

| Variable                                  | Non-BSI Group (n = 68) | BSI Group (n = 27) | P Value |
|-------------------------------------------|------------------------|--------------------|---------|
| **Symptoms**                              | **              |                    |         |
| Reported symptoms for >14 d               | 41 (60.2)             | 9 (33.3)           | .02     |
| Chills                                    | 4 (5.8)               | 24 (85.7)          | <.001   |
| General malaise                           | 2 (2.9)               | 26 (92.8)          | <.001   |
| Altered mental status                     | 0                     | 4 (14.8)           | <.001   |
| **Signs at physical examination**         | **              |                    |         |
| Erythema                                  | 46 (67.6)             | 18 (66.6)          | .93     |
| Tenderness                                | 31 (45.5)             | 17 (62.9)          | .13     |
| Swelling                                  | 21 (30.8)             | 12 (44.4)          | .21     |
| Warmth                                    | 4 (5.8)               | 3 (11.1)           | .38     |
| Purulent drainage                         | 6 (22.2)              | 18 (66.6)          | .67     |
| Fluctuance                                | 3 (4.4)               | 14 (11.1)          | .08     |
| Surgical incision dehiscence              | 9 (13.2)              | 2 (7.4)            | .42     |
| Lead or generator erosion                 | 25 (36.7)             | 3 (11.1)           | .01     |
| **Vital signs at initial evaluation**      | **              |                    |         |
| Maximum temperature, median (IQR), °C     | 36.6 (36.5–36.8)      | 38.1 (36.52–38.8)  | <.001   |
| Maximum temperature >38.3°C or <36°C       | 1 (1.4)               | 11 (40.7)          | <.001   |
| Pulse rate, median (IQR), beats/min       | 70 (62–80)            | 75 (85–100)        | .08     |
| Pulse rate, >90 beats/min                | 3 (4.4)               | 7 (25.9)           | <.001   |
| Respirations, median (IQR), respirations/min | 18 (16–19)    | 18 (17.5–22.5)     | .03     |
| Respirations >20/min                      | 11 (16.4)             | 10 (38.4)          | .02     |
| SBP, median (IQR), mm Hg                  | 120 (108–131.5)       | 112 (85–125)       | .02     |
| SBP <90 mm Hg or ≥40-mm Hg drop from baseline | 3 (4.4)          | 11 (40.7)          | <.001   |
| Septic shock                              | 0                     | 6 (21.4)           | <.001   |
| Organ failure                             | 1 (1.4)               | 11 (42.3)          | <.001   |
| **Laboratory data at initial presentation** | **              |                    |         |
| WBC count, median (IQR), ×10^9/L          | 7.2 (5.6–9.1)         | 12.4 (8.7–16.1)    | <.001   |
| WBC count >12 ×10^9/L or ≤4 ×10^9/L       | 2 (2.9)               | 16 (59.2)          | <.001   |
| Serum creatinine, median (IQR), mg/dL     | 1 (0.8–1.3)           | 1.1 (0.9–1.7)      | .04     |
| BUN, median (IQR), mg/dL                  | 20 (14–26)            | 1.25 (17.7–37)     | .06     |
| AST, median (IQR), U/L                    | 22 (20–27)            | 29 (25–47)         | .02     |

Abbreviations: AST, aspartate aminotransferase; BSI, bloodstream infection; CIED, cardiovascular implantable electronic device; IQR, interquartile range; SBP, systolic blood pressure; BUN, blood urea nitrogen; WBC, white blood cell.

*Data represent No. (%) of patients, unless otherwise specified.

*Significant at P < .05.
Overall, in the non-BSI group, positive intraoperative device/tissue cultures were more common in patients in whom antibiotics were initially withheld until device extraction (79.4% vs 58.6% in their antibiotic-treated counterparts), however, this difference was not statistically significant ($P = .061$).

**Microbiology**

Organisms isolated in blood and operative cultures from the 95 cases of CIED pocket and BSI are shown in Table 5. The median time to blood culture positivity was 16 (IQR, 11.5–35.5) hours, and the median duration of BSI was 2.5 (1–4.25) days. In patients with positive blood and intraoperative cultures, concordance was reported in 80% (20 of 25) of cases. Of the remaining 5 cases, 2 had discrepant results between blood and intraoperative cultures; and 3 had negative intraoperative culture results. All 5 of these cases received antibiotics at the time of presentation.

**DISCUSSION**

Our study findings suggest that patients with CIED pocket infection who present with SIRS criteria (fever or hypothermia, tachycardia, tachypnea, and leukocytosis or leukopenia) and/or hypotension (systolic blood pressure <90 mm Hg or a >40–mm Hg drop from baseline) are more likely to have underlying BSI. Consequently, patients presenting with these features should be started on empiric antimicrobial therapy once blood cultures have been obtained. On the contrary, the absence of these features suggests that underlying BSI is less likely, and it may be reasonable to withhold starting empiric antimicrobial therapy. In our cohort, none of the patients who were deemed clinically stable (absence of SIRS criteria or hypotension) and in whom empiric antibiotics were withheld (for a median of 2 days) experienced clinical progression or hemodynamic deterioration while awaiting device extraction. Furthermore, in the non-BSI group, the percentage of cases with significant microbial growth...
Predictors of BSI in patients presenting with CIED pocket infection have not been specifically evaluated in prior publications. Le et al [15] analyzed risk factors for CIED-related infective endocarditis (CIED-IE) in an earlier investigation and reported that use of immunomodulator therapy and hemodialysis were associated with a higher risk of CIED-IE. These patients were more likely to present with leukocytosis, fever, or malaise compared to non-CIED-IE cases. Interestingly, patients with CIED-IE were less likely to present with infection at the generator pocket site, suggesting that the predominant mechanism of IE in these cases was hematogenous seeding of device leads or heart valves from distant sources of bacteremia.

Distinguishing patients with CIED pocket infection who may have underlying BSI from those who do not, before availability of blood culture results, is crucial, because patients with BSI have poorer outcomes, and delays in starting empiric antibiotics and device extraction can have detrimental effects [16].

In current practice, empiric antimicrobial therapy before device removal is based on personal discretion of the treating physician without much evidence to guide the decision-making process. This approach is concerning from a stewardship perspective, as routine administration of empiric antibiotics in stable patients, with no risk factors for underlying BSI, can negatively impact the yield of blood and operative specimen cultures. Consequently, pathogen-specific therapy is not an option in patients with negative cultures, who are often treated with broad-spectrum antimicrobial therapy [9]. Such approach opposes current efforts to minimize antibiotic overuse in an attempt to reduce antimicrobial resistance.

Based on our study findings and review of the published literature, we recommend obtaining 2 sets of blood cultures in all patients regardless of clinical presentation. Patients with ≥1 predictor of underlying BSI should be started on empiric antibiotic therapy directed against staphylococci. Whether or not addition of aerobic gram-negative coverage is necessary should be determined on a case-by-case basis. For patients without any positive predictors of underlying BSI, antibiotic therapy may be withheld to optimize the intraoperative culture yield. All patients with confirmed CIED infection, regardless of clinical presentation, should be evaluated as soon as possible for complete device extraction [16].

Our study is retrospective, and its design has inherent limitations. Considering the large tertiary academic nature of our practice, there is also a possibility of referral bias. It is certainly possible that patients referred to our medical center were sicker and more likely to have received prior courses of antimicrobial therapy and prior management, such as partial removal of cardiac device. This might skew our data compared with overall cases of CIED infection, which might affect subsequent interpretation of results. Owing to the small sample size, we were
unable to develop a robust scoring system to predict underlying BSI in patients presenting with CIED pocket infection.

In conclusion, our study findings suggest that patients with CIED pocket infection who are afebrile, hemodynamically stable, and have normal leukocyte counts at admission are unlikely to have underlying BSI. Therefore, it may be reasonable to withhold antimicrobial therapy in these patients to optimize the intraoperative culture yield, provided that device extraction is planned in the next 2–3 days.

Notes

Financial support. Dr. Sohail reports receiving funds from TYRX Inc. and Medtronic for prior research unrelated to this study administered according to a sponsored research agreement between Mayo Clinic and study sponsor that prospectively defined the scope of the research effort and corresponding budget; and honoraria/consulting fees from Medtronic Inc., Spectranetics, Boston Scientific Corp., and Aziyo Biologics, Inc.

Potential conflicts of interest. P. A. F. reports honoraria/consultant fees from Medtronic, Guidant, and Astra Zeneca; research grant from Medtronic, Astra Zeneca via Beth Israel, Guidant, St Jude, Bard; and intellectual property rights with Bard EP, Hewlett Packard, and Medical Positioning. L. M. B. reports royalty payments (authorship) from UpToDate (<$20,000) and consultant payments from Medtronic, Spectranetics, Boston Scientific, and Aziyo Biologics (all <$20,000). All other authors report no conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Greenspon AJ, Patel JD, Lau E, et al. 16-Year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011; 58:1001–6.
2. Sohail MR, Hussain S, Le KY, et al; Mayo Cardiovascular Infections Study Group. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. J Interv Card Electrophysiol 2011; 31:171–83.
3. Welch M, Uldan DZ, Greenspon AJ, et al; MEDIC Investigators. Variability in clinical features of early versus late cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol 2014; 37:955–62.
4. Baddour LM, Epstein AE, Erickson CC, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; Council on Cardiovascular Disease in Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care; American Heart Association. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458–77.
5. Huseen AA, Baghdy YB, Wazni OM, et al. Microbiology of cardiac implantable electronic device infections. JACC Clin Electrophysiol 2016; 2:498–505. doi: 10.1016/j.jacep.2016.01.019.
6. Bongiorni MG, Tascini C, Tagliaferri E, et al. Microbiology of cardiac implantable electronic device infections. Europace 2012; 14:1334–9.
7. Podoleau C, Deharo JC. Management of cardial implantable electronic device infection. Arrhythm Electrophysiol Rev 2014; 3:184–9.
8. Naggal A, Patel R, Greenwood-Quaintance KE, et al. Usefulness of sonication of cardiovascular implantable electronic devices to enhance microbial detection. Am J Cardiol 2015; 115:912–7.
9. Esquer Garrigos Z, George MP, Farid S, et al. Diagnostic evaluation and management of culture-negative cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol 2018 May 31. doi: 10.1111/pace.13397. [Epub ahead of print]
10. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015; 40:277–83.
11. DeSimone DC, Sohail MR. Approach to diagnosis of cardiovascular implantable electronic device infection. J Clin Microbiol 2018; 56. pii: e01683-17. doi: 10.1128/JCM.01683-17. Print 2018 Jul.
12. Bekeris LG, Tworek JA, Walsh MK, Valenstein PN. Trends in blood culture contamination: a College of American Pathologists Q-tracks study of 356 institutions. Arch Pathol Lab Med 2005; 129:1222–5.
13. Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007; 357:654–63.
14. Obeid KM, Sepunar S, Khatib R. Long-term outcomes of cardiovascular implantable electronic devices in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2012; 35:961–5.
15. LE KY, Sohail MR, Friedman PA, et al; Mayo Cardiovascular Infections Study Group. Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol 2011; 34:450–9.
16. Le KY, Sohail MR, Friedman PA, et al; Mayo Cardiovascular Infections Study Group. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011; 8:1678–85.